Progestogen

Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances

Retrieved on: 
Thursday, December 2, 2021
Trial of the century, Genotype, CEO, Behavior, PBPK, US Food Sovereignty Alliance, Technology, Industry, Lactation, Cerebrospinal fluid, Therapy, Pregnancy, Nasdaq, GLOBE, Drug, FDA, Pediatrics, Progestogen, Drug development, Doctor of Philosophy, Drug discovery, Pharmaceutical industry, Medical device

We are excited to offer new capabilities to advance modern drug development with the launch of our latest Simcyp Simulator, said William F. Feehery, Ph.D., CEO of Certara.

Key Points: 
  • We are excited to offer new capabilities to advance modern drug development with the launch of our latest Simcyp Simulator, said William F. Feehery, Ph.D., CEO of Certara.
  • This latest update aligns with recent regulatory guidances, so that we can help accelerate the development and approval of crucial therapies to patients.
  • Version 21 also features updates to Simcyp modules for pediatrics, pregnancy, lactation, biologic drugs, virtual bioequivalence and in vitro-in vivo correlation.
  • Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Avion Pharmaceuticals recognizes Menopause Awareness Month by announcing the addition of Divigel® (estradiol gel) 0.1% to their product portfolio

Retrieved on: 
Monday, September 20, 2021
Dementia, Flash, Myocardial infarction, Megasphaera, National Center for Biotechnology Information, Therapy, Health, Stroke, WHI, FDA, Pulmonary embolism, Multimedia, Patient, Institute, MI, Progestogen, CEO, NPA, LLC, Woman, National Center for Health Research, DC, CE, Menopause, Prenatal care, DVT, Breast cancer, Estimation, MPA, Reproductive health, Pharmaceutical industry, Birth control, Dietary supplement

ALPHARETTA, Ga., Sept. 20, 2021 /PRNewswire/ --Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced the addition of Divigel (estradiol gel) 0.1%the #1 prescribed transdermal estrogen gel*to the company's growing women's health portfolio.

Key Points: 
  • ALPHARETTA, Ga., Sept. 20, 2021 /PRNewswire/ --Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced the addition of Divigel (estradiol gel) 0.1%the #1 prescribed transdermal estrogen gel*to the company's growing women's health portfolio.
  • The product is supplied in a discreet gel pack and is applied once daily to a small area of the upper thigh.
  • As a part of their observance of Menopause Awareness Month, Avion will present a product theater on Friday, Sept. 24, during the North American Menopause Society Annual Meeting in Washington, DC.
  • Divigel (estradiol gel) 0.1% is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Hormone Replacement Therapy Market to Reach $46.50 Bn, Globally, by 2027 at 5.1% CAGR: Allied Market Research

Retrieved on: 
Monday, March 1, 2021
Organ systems, Clinical medicine, Medicine, Hepatotoxins, Prolactin releasers, Estrogens, Estranes, Phenols, Hypogonadism, Hormone replacement therapy, Transgender hormone therapy, Progestogen

- Rise in Prevalence of menopausal disorder, increasingawareness about post-menopausal issues among women, and new launches of hormone replacement therapy fuel the growth of the global hormone replacement therapy market.

Key Points: 
  • - Rise in Prevalence of menopausal disorder, increasingawareness about post-menopausal issues among women, and new launches of hormone replacement therapy fuel the growth of the global hormone replacement therapy market.
  • PORTLAND, Ore., March 1, 2021 /PRNewswire/ -- Allied Market Research published a report, titled," Hormone Replacement Therapy Market by Therapy Type (Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, and Progestogen Hormone Replacement Therapy), Route of Administration (Oral, Parenteral, and Others), and Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others): Global Opportunity Analysis and Industry Forecast 20202027."
  • Rise in prevalence of menopausal disorder, increasingawareness about post-menopausal issues among women, and new launches of hormone replacement therapy fuel the growth of the global hormone replacement therapy market.
  • Based on therapy type, the estrogen hormone replacement therapy segment contributed to more than two-fifths of the global hormone replacement therapy market share in 2019, and is expected to rule the roost by the end of 2027, owing to rise in use of estradiol products in women during post-menopause.